已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting

作者
Eiko Iwasa,Yu Fujiyoshi,Yuki Kubota,Ryota Kimura,Rebecca E. Chandler,Henric Taavola,G. Niklas Norén,Rika Wakao
出处
期刊:Drug Safety [Adis, Springer Healthcare]
卷期号:43 (11): 1121-1131 被引量:42
标识
DOI:10.1007/s40264-020-00968-7
摘要

INTRODUCTION: Increased post-marketing reports of interstitial lung disease in Japan have been recognized. An understanding of its regional groundings can be important for the global pharmacovigilance community. OBJECTIVE: The objective of this study was to explore the correlation between high rates of interstitial lung disease reporting and regulatory actions in Japan. METHODS: Post-marketing interstitial lung disease-related label changes and interstitial lung disease reports were classified by the anatomical therapeutic chemical classification groups of the suspected drugs. Regulatory actions for the top interstitial lung disease-reporting drugs were compared. The interstitial lung disease reporting patterns of protein kinase inhibitors were compared to those of methotrexate. RESULTS: Interstitial lung disease-related label changes predominantly occurred for drugs in the anatomical therapeutic chemical classification groups L, J, C, and herbal medicines. Interstitial lung disease was reported most frequently for L group, especially for the protein kinase inhibitors. The regulatory actions for those drugs with the highest number of interstitial lung disease reports (methotrexate, protease kinase inhibitors, gemcitabine, docetaxel) plus monoclonal antibodies were analyzed. The ratio of interstitial lung disease reports to all reports over time was initially high in the re-examination period, while it was constantly low after the period expired. The increase in interstitial lung disease reporting was observed for the drugs for which interstitial lung disease was designated as a priority item in the use-results survey. Methotrexate had more interstitial lung disease reports with multiple suspected drugs and fewer reports with high completeness than the protease kinase inhibitors. CONCLUSIONS: The high rates of interstitial lung disease reporting derived from mainly the anatomical therapeutic chemical classification group L drugs. Interstitial lung disease is the targeted adverse drug reaction in the use-results survey mandated in the re-examination of those drugs. This system provides at least one explanation for the high reporting of interstitial lung disease in Japan.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Qi完成签到 ,获得积分10
2秒前
alex的应助被浪迹采纳,获得30
2秒前
zzw完成签到,获得积分10
3秒前
yy完成签到 ,获得积分10
3秒前
4秒前
wuwu完成签到,获得积分10
4秒前
Kkicesong发布了新的文献求助10
5秒前
6秒前
7秒前
u558069发布了新的文献求助60
10秒前
10秒前
ll发布了新的文献求助10
10秒前
kali发布了新的文献求助10
11秒前
带带大袋鼠关注了科研通微信公众号
12秒前
MYC007完成签到 ,获得积分10
12秒前
luo完成签到,获得积分0
12秒前
烤地瓜大师完成签到 ,获得积分10
13秒前
momo发布了新的文献求助10
14秒前
3921337477的应助被u283987采纳,获得60
14秒前
15秒前
15秒前
16秒前
白夜完成签到 ,获得积分10
16秒前
英俊h发布了新的文献求助20
17秒前
Y_完成签到 ,获得积分10
17秒前
CodySky完成签到,获得积分10
17秒前
Ade完成签到,获得积分10
19秒前
加载中完成签到 ,获得积分10
19秒前
盲点完成签到,获得积分10
20秒前
王化省发布了新的文献求助10
20秒前
Crazyjmj完成签到,获得积分10
20秒前
小媛完成签到 ,获得积分20
21秒前
梨凉完成签到,获得积分10
23秒前
24秒前
胡明轩完成签到 ,获得积分10
24秒前
学霸业的应助被科研通管家采纳,获得10
24秒前
u283987发布了新的文献求助60
24秒前
田様的应助被科研通管家采纳,获得10
24秒前
学霸业的应助被科研通管家采纳,获得10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184867
求助须知:如何正确求助?哪些是违规求助? 9573803
关于积分的说明 21833148
捐赠科研通 7782177
什么是DOI,文献DOI怎么找? 3434414
关于科研通互助平台的介绍 2558563
邀请新用户注册赠送积分活动 2481067